Impact of Chronic Kidney Disease and Acute Kidney Injury on Safety and Outcomes of CAR T-Cell Therapy in Lymphoma Patients
- 18 July 2022
- journal article
- research article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 22 (11) , 863-868
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design studyThe Lancet, 2020
- Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid RecoveryTransplantation and Cellular Therapy, 2020
- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell LymphomaNew England Journal of Medicine, 2020
- Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell LymphomaAmerican Journal of Kidney Diseases, 2020
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell LymphomaNew England Journal of Medicine, 2019
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaNew England Journal of Medicine, 2017
- Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic LeukemiaCritical Care Medicine, 2017
- Medical management of side effects related to CAR T cell therapy in hematologic malignanciesExpert Review of Hematology, 2016
- Tumor Lysis Syndrome and Acute Kidney Injury: Evaluation, Prevention, and ManagementAmerican Journal of Kidney Diseases, 2010